Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

DARE - Daré Bioscience, Inc. Последние новости | Finranks

Home

DARE

(DARE)

NCM – Цена в реальном времени. Валюта: USD

1.55

+0.04 (2.65%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

1.58

+0.04 (2.26%)

После закрытия: Mar 27, 2026, 7:35 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Видео

No Data

There is no data to display

Пресс-релизы

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts

On National Viagra Day, Women Finally Claim Their Turn:

On National Viagra Day, Women Finally Claim Their Turn:

DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women's health

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women's health Access the segment here